BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32535161)

  • 1. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.
    Jaccard M; Zilli T; Dubouloz A; Escude L; Jorcano S; Linthout N; Bral S; Verbakel W; Bruynzeel A; Björkqvist M; Minn H; Tsvang L; Symon Z; Lencart J; Oliveira A; Ozen Z; Abacioglu U; Pérez-Moreno JM; Rubio C; Rouzaud M; Miralbell R
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1047-1054. PubMed ID: 32535161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
    Dubouloz A; Rouzaud M; Tsvang L; Verbakel W; Björkqvist M; Linthout N; Lencart J; Pérez-Moreno JM; Ozen Z; Escude L; Zilli T; Miralbell R
    Radiat Oncol; 2018 Jun; 13(1):114. PubMed ID: 29921291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment.
    Quan EM; Li X; Li Y; Wang X; Kudchadker RJ; Johnson JL; Kuban DA; Lee AK; Zhang X
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1169-78. PubMed ID: 22704703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
    Scobioala S; Kittel C; Elsayad K; Kroeger K; Oertel M; Samhouri L; Haverkamp U; Eich HT
    Radiat Oncol; 2019 Aug; 14(1):143. PubMed ID: 31399115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
    Ruggieri R; Naccarato S; Stavrev P; Stavreva N; Fersino S; Giaj Levra N; Mazzola R; Mancosu P; Scorsetti M; Alongi F
    Br J Radiol; 2015 Oct; 88(1054):20140736. PubMed ID: 26235142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer.
    Davidson MT; Blake SJ; Batchelar DL; Cheung P; Mah K
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1550-8. PubMed ID: 21543164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
    Benhmida S; Beneux A; Udrescu C; Rouviere O; Horn S; Enachescu C; Lapierre A; Chapet O
    Br J Radiol; 2021 Nov; 94(1127):20210142. PubMed ID: 34283647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
    Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
    Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric comparison of two treatment planning systems for spine SBRT.
    Lee YK; Munawar I; Mashouf S; Sahgal A; Ruschin M
    Med Dosim; 2020 Spring; 45(1):77-84. PubMed ID: 31376988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
    Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric modulated arc therapy treatment planning of thoracic vertebral metastases using stereotactic body radiotherapy.
    Mallory M; Pokhrel D; Badkul R; Jiang H; Lominska C; Wang F
    J Appl Clin Med Phys; 2018 Mar; 19(2):54-61. PubMed ID: 29349867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
    Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
    Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
    Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.